New Presentation ...- Upcoming milestones are identified for OTENA - acute
- Notice the asteriks on 352 in the pipeline (also being validated for OTENA)
- Robust sales potential is being presented in a very obscure way, in a present dollar amount for peak sales, for USA only, and mostly for post-op (and that's the only way you'd see a number close to $1 BB). No other way to explain it when we're talking 50% adoption rate for post-op. No problem, they are trying to advertise to a minimum and that's fine for me.
- Patent protected to 2043
- Trademark application for 2 brand names - That's LEMBAYLI and GOPIVEO for the USA and globally - trademarks registered on December 1, 2021.
- One additional trademark called SULREVIQ but they are not talking about it. Likely only for Canada or maybe they scrapped it. Note, it was registered in Canada on June 9, 2021.